About Us Strategy & Mission Our Values Our People Our Board Our Collaborations Contact Our Programmes Overview Pipeline C. difficile Infection Gonorrhoea ESKAPE Programme Clinical Trials Stewardship Compassionate Use Our Science Discuva Platform Publications Investors Investor Centre Press Releases Financial Reports & Filings Email Alerts Events & Presentations Share Price Data Shareholder Information Analyst Coverage Corporate Governance AIM Rule 26 Advisers Careers
Press Releases Our latest press releases are available to read in this section Press Releases Date Range Explore Search Press Releases / 02 Aug 2018 Phase 2 Clinical Data Published Showing Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile Infection Press Releases / 10 Jul 2018 Summit Awarded up to $4.5 Million Grant from CARB-X for Development of New Mechanism Gonorrhoea Antibiotics Press Releases / 27 Jun 2018 Summit Announces PhaseOut DMD Did Not Meet Primary Endpoint Press Releases / 11 Jun 2018 Summit Unveils Second Novel Target for Gonorrhoea at ASM Microbe 2018 Press Releases / 07 Jun 2018 Result of AGM Press Releases / 05 Jun 2018 Financial Results for First Quarter Ended 30 April 2018 Press Releases / 23 Apr 2018 Summit Highlights Discovery of a Series of New Mechanism Antibiotics for the Treatment of Gonorrhoea at ECCMID 2018 Press Releases / 20 Apr 2018 Summit Presents New 24-Week Analyses from PhaseOut DMD at 2018 AAN Annual Meeting Press Releases / 19 Apr 2018 Summit Completes Dosing of Ezutromid in PhaseOut DMD Clinical Trial Press Releases / 11 Apr 2018 Fourth Quarter and Full Year Results for 2017/18 Press Releases / 28 Mar 2018 Summit Therapeutics Selected for Emerging Science Presentation at the 2018 AAN Annual Meeting Press Releases / 27 Mar 2018 Summit Announces Placement of £15.0 Million of Ordinary Shares << 1 2 3 … 23 24 >>
Press Releases / 02 Aug 2018 Phase 2 Clinical Data Published Showing Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile Infection Press Releases / 10 Jul 2018 Summit Awarded up to $4.5 Million Grant from CARB-X for Development of New Mechanism Gonorrhoea Antibiotics Press Releases / 27 Jun 2018 Summit Announces PhaseOut DMD Did Not Meet Primary Endpoint Press Releases / 11 Jun 2018 Summit Unveils Second Novel Target for Gonorrhoea at ASM Microbe 2018 Press Releases / 07 Jun 2018 Result of AGM Press Releases / 05 Jun 2018 Financial Results for First Quarter Ended 30 April 2018 Press Releases / 23 Apr 2018 Summit Highlights Discovery of a Series of New Mechanism Antibiotics for the Treatment of Gonorrhoea at ECCMID 2018 Press Releases / 20 Apr 2018 Summit Presents New 24-Week Analyses from PhaseOut DMD at 2018 AAN Annual Meeting Press Releases / 19 Apr 2018 Summit Completes Dosing of Ezutromid in PhaseOut DMD Clinical Trial Press Releases / 11 Apr 2018 Fourth Quarter and Full Year Results for 2017/18 Press Releases / 28 Mar 2018 Summit Therapeutics Selected for Emerging Science Presentation at the 2018 AAN Annual Meeting Press Releases / 27 Mar 2018 Summit Announces Placement of £15.0 Million of Ordinary Shares
Press Releases / 02 Aug 2018 Phase 2 Clinical Data Published Showing Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile Infection
Press Releases / 10 Jul 2018 Summit Awarded up to $4.5 Million Grant from CARB-X for Development of New Mechanism Gonorrhoea Antibiotics
Press Releases / 23 Apr 2018 Summit Highlights Discovery of a Series of New Mechanism Antibiotics for the Treatment of Gonorrhoea at ECCMID 2018
Press Releases / 20 Apr 2018 Summit Presents New 24-Week Analyses from PhaseOut DMD at 2018 AAN Annual Meeting
Press Releases / 28 Mar 2018 Summit Therapeutics Selected for Emerging Science Presentation at the 2018 AAN Annual Meeting
